CytoDyn Reports Significant Fibrosis Reversal in SMC Lab Studies
In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstrating the efficacy of leronlimab (a CCR5 antagonist) in liver disease models. Using our STAM (MASH-HCC) and CCl₄-induced liver fibrosis models, leronlimab monotherapy successfully reversed liver fibrosis—an area with significant unmet medical need.
These findings suggest that leronlimab’s anti-fibrotic potential may extend beyond liver disease, with possible implications for other fibrotic conditions, such as those affecting the lungs and heart.
We look forward to its continued development and success.
For more details, please see the press release: